MX2020000029A - Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon. - Google Patents
Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon.Info
- Publication number
- MX2020000029A MX2020000029A MX2020000029A MX2020000029A MX2020000029A MX 2020000029 A MX2020000029 A MX 2020000029A MX 2020000029 A MX2020000029 A MX 2020000029A MX 2020000029 A MX2020000029 A MX 2020000029A MX 2020000029 A MX2020000029 A MX 2020000029A
- Authority
- MX
- Mexico
- Prior art keywords
- mussel adhesive
- montelukast
- combinations
- topical formulations
- adhesive proteins
- Prior art date
Links
- 108010004563 mussel adhesive protein Proteins 0.000 title abstract 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title 1
- 229960005127 montelukast Drugs 0.000 title 1
- 239000012049 topical pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003988 mussel adhesive protein Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017091819 | 2017-07-05 | ||
| CN2018087058 | 2018-05-16 | ||
| PCT/CN2018/094441 WO2019007356A1 (en) | 2017-07-05 | 2018-07-04 | TOPICAL FORMULATIONS COMPRISING MONTELUKAST AND COMBINATIONS WITH MOLD ADHESION PROTEINS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020000029A true MX2020000029A (es) | 2020-08-06 |
Family
ID=64949737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000029A MX2020000029A (es) | 2017-07-05 | 2018-07-04 | Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11672792B2 (enExample) |
| EP (1) | EP3648767A4 (enExample) |
| JP (1) | JP7288404B2 (enExample) |
| KR (1) | KR102785243B1 (enExample) |
| CN (3) | CN110312513B (enExample) |
| AU (1) | AU2018295944B2 (enExample) |
| CA (1) | CA3068818A1 (enExample) |
| MA (1) | MA52924A (enExample) |
| MX (1) | MX2020000029A (enExample) |
| MY (1) | MY201703A (enExample) |
| SG (1) | SG11201911841PA (enExample) |
| TW (1) | TWI874298B (enExample) |
| WO (1) | WO2019007356A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3648767A4 (en) * | 2017-07-05 | 2021-04-28 | Jiangyin Mucocare Pharmaceutical Co., Ltd | TOPICAL FORMULATIONS WITH MONTELUKAST AND COMBINATIONS WITH SHELL ADHESION PROTEINS |
| SI3678705T1 (sl) | 2018-09-14 | 2023-10-30 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | Konjugati montelukasta in peptidov |
| MA54707A (fr) * | 2019-01-10 | 2021-11-17 | Jiangyin Mucocare Pharmaceutical Co Ltd | Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes |
| MX2022003057A (es) * | 2019-09-14 | 2022-06-16 | Jiangyin Usun Pharmaceutical Co Ltd | Nuevos peptidos. |
| CN114929259A (zh) * | 2019-12-02 | 2022-08-19 | 艾缇亚(上海)制药有限公司 | 新型多功能寡肽 |
| CN114929283A (zh) * | 2019-12-02 | 2022-08-19 | 艾缇亚(上海)制药有限公司 | 肽和多糖的新缀合物 |
| BR112022015199A2 (pt) | 2020-02-03 | 2022-10-11 | Taro Pharma Ind | Formulações tópicas de montelucaste |
| US12233055B2 (en) | 2020-02-03 | 2025-02-25 | Taro Pharmaceutical Industries Ltd. | Topical Montelukast formulations |
| EP4228641A1 (en) | 2020-10-13 | 2023-08-23 | Diomed Developments Limited | Gel formulations comprising montelukast |
| CN114588267A (zh) * | 2020-12-04 | 2022-06-07 | 江苏恒瑞医药股份有限公司 | 一种含酰胺类局部麻醉药的药物组合物 |
| US20240165247A1 (en) * | 2021-03-17 | 2024-05-23 | Jiangyin Usun Pharmaceutical Co., Ltd. | New peptide conjugates |
| WO2022193186A1 (en) * | 2021-03-17 | 2022-09-22 | Jiangyin Usun Pharmaceutical Co., Ltd. | New diagnostic and therapeutic agents |
| TW202337464A (zh) * | 2021-08-06 | 2023-10-01 | 大陸商安利提沙（上海）製藥有限公司 | 免疫不全病症的新治療 |
| CN116421547A (zh) * | 2023-03-09 | 2023-07-14 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 一种孟鲁司特钠外用乳膏剂的制备及其在炎症性皮肤病中的应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2213989C (en) * | 1995-12-28 | 2007-05-29 | Yoshitomi Pharmaceutical Industries Ltd. | External preparation for topical administration |
| US20030207932A1 (en) | 2002-05-03 | 2003-11-06 | Morris Mann | Compositions that prevent post-traumatic hyperpigmentation and methods related thereto |
| ATE529125T1 (de) * | 2003-08-07 | 2011-11-15 | Healor Ltd | Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung |
| US6987170B1 (en) * | 2004-08-09 | 2006-01-17 | Battelle Energy Alliance, Llc | Cloning and expression of recombinant adhesive protein Mefp-1 of the blue mussel, Mytilus edulis |
| WO2007126865A2 (en) * | 2006-03-30 | 2007-11-08 | Patrin Pharma | Leukotriene antagonists via nasal drug delivery |
| CN1961867A (zh) | 2006-11-16 | 2007-05-16 | 徐英权 | 孟鲁司特钠的颗粒剂型 |
| WO2008106081A1 (en) * | 2007-02-26 | 2008-09-04 | Larry Schlesinger | Topical formulations containing leukotriene receptor antagonist and use for treatment or prevention of capsular contracture, scarring or hyperpigmentation |
| WO2008105803A1 (en) | 2007-02-26 | 2008-09-04 | Larry Schlesinger | Topical formulations containing leukotriene receptor antagonist and uses thereof |
| WO2009137555A1 (en) | 2008-05-06 | 2009-11-12 | Schlesinger S Larry | Topical and injectable formulations comprising leukotriene receptor antagonist and uses thereof |
| CA2653011A1 (en) * | 2008-12-03 | 2010-06-03 | Apotex Technologies Inc | Method and apparatus for packaging and dispensing pharmaceuticals |
| GB0915319D0 (en) | 2009-09-03 | 2009-10-07 | Sharma Anant | Combination medicament |
| CN101773503A (zh) | 2010-01-12 | 2010-07-14 | 北京华禧联合科技发展有限公司 | 一种白三烯拮抗剂和抗组胺药组合物 |
| CA2802853C (en) | 2010-06-16 | 2016-07-26 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation |
| CN102895661A (zh) * | 2011-07-28 | 2013-01-30 | 中国科学院上海药物研究所 | 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途 |
| JP6200432B2 (ja) | 2011-12-26 | 2017-09-20 | エスケー ケミカルズ カンパニー リミテッド | モンテルカストまたはその薬学的に許容可能な塩を含む経口投与用フィルム |
| CN103239450B (zh) | 2012-02-07 | 2014-11-26 | 齐鲁制药有限公司 | 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法 |
| EP3308835B1 (en) * | 2013-03-13 | 2020-01-01 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of traumatic injury |
| CN103655497B (zh) | 2013-12-18 | 2018-05-29 | 北京华禧联合科技发展有限公司 | 一种孟鲁司特钠口腔崩解片及其制备方法 |
| WO2016021599A1 (ja) * | 2014-08-04 | 2016-02-11 | 日東電工株式会社 | 液性免疫誘導促進用組成物及びワクチン医薬組成物 |
| CN105769825A (zh) | 2014-12-24 | 2016-07-20 | 广州朗圣药业有限公司 | 一种孟鲁司特钠的口腔膜剂及其制备方法 |
| CN105878215A (zh) | 2014-12-31 | 2016-08-24 | 天津康鸿医药科技发展有限公司 | 一种稳定的孟鲁司特口腔速溶膜及其制备方法和用途 |
| KR101892340B1 (ko) * | 2015-03-13 | 2018-08-27 | 경희대학교 산학협력단 | 몬테루카스트의 생체이용률을 개선시키기 위한 방법 |
| CN104784157B (zh) | 2015-04-04 | 2018-06-26 | 齐鲁制药有限公司 | 一种稳定的孟鲁司特口腔薄膜剂 |
| WO2017011983A1 (zh) * | 2015-07-20 | 2017-01-26 | 江阴市本特塞缪森生命科学研究院有限公司 | 贻贝粘蛋白用于皮肤和皮肤附属器官的防护 |
| BR112018000953A2 (pt) | 2015-07-20 | 2018-09-11 | Bengt I. Samuelsson Institute Of Life Science Research | produto de proteína adesiva de mexilhão e aplicações do mesmo na supressão de inflamações de pele |
| WO2017147067A1 (en) * | 2016-02-22 | 2017-08-31 | Board Of Regents, The University Of Texas System | Antimicrobial compositions and uses thereof |
| US10548837B1 (en) | 2016-05-04 | 2020-02-04 | Taro Pharmaceutical Industries Ltd. | Topical montelukast for treatment of atopic dermatitis |
| EP3648767A4 (en) * | 2017-07-05 | 2021-04-28 | Jiangyin Mucocare Pharmaceutical Co., Ltd | TOPICAL FORMULATIONS WITH MONTELUKAST AND COMBINATIONS WITH SHELL ADHESION PROTEINS |
| JP7742226B2 (ja) * | 2018-05-28 | 2025-09-19 | ジャンイン ユスン ファーマシューティカル カンパニー，リミテッド | 新たな医薬品使用 |
| SI3678705T1 (sl) * | 2018-09-14 | 2023-10-30 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | Konjugati montelukasta in peptidov |
| MA54707A (fr) * | 2019-01-10 | 2021-11-17 | Jiangyin Mucocare Pharmaceutical Co Ltd | Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes |
-
2018
- 2018-07-04 EP EP18827979.8A patent/EP3648767A4/en active Pending
- 2018-07-04 CN CN201880002883.6A patent/CN110312513B/zh active Active
- 2018-07-04 AU AU2018295944A patent/AU2018295944B2/en active Active
- 2018-07-04 CA CA3068818A patent/CA3068818A1/en active Pending
- 2018-07-04 SG SG11201911841PA patent/SG11201911841PA/en unknown
- 2018-07-04 MX MX2020000029A patent/MX2020000029A/es unknown
- 2018-07-04 KR KR1020207003363A patent/KR102785243B1/ko active Active
- 2018-07-04 JP JP2019572791A patent/JP7288404B2/ja active Active
- 2018-07-04 CN CN202210843681.2A patent/CN115300508A/zh active Pending
- 2018-07-04 MA MA052924A patent/MA52924A/fr unknown
- 2018-07-04 US US16/628,170 patent/US11672792B2/en active Active
- 2018-07-04 MY MYPI2020000043A patent/MY201703A/en unknown
- 2018-07-04 CN CN202110903665.3A patent/CN113491696A/zh active Pending
- 2018-07-04 WO PCT/CN2018/094441 patent/WO2019007356A1/en not_active Ceased
- 2018-07-05 TW TW107123334A patent/TWI874298B/zh active
-
2023
- 2023-05-01 US US18/310,020 patent/US20230404992A1/en not_active Abandoned
-
2024
- 2024-12-11 US US18/977,212 patent/US20250302818A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018295944B2 (en) | 2023-12-14 |
| TW201919633A (zh) | 2019-06-01 |
| KR102785243B1 (ko) | 2025-03-26 |
| CN110312513A (zh) | 2019-10-08 |
| KR20200039677A (ko) | 2020-04-16 |
| CN113491696A (zh) | 2021-10-12 |
| TWI874298B (zh) | 2025-03-01 |
| EP3648767A1 (en) | 2020-05-13 |
| CN110312513B (zh) | 2022-07-08 |
| AU2018295944A1 (en) | 2020-02-20 |
| MY201703A (en) | 2024-03-13 |
| SG11201911841PA (en) | 2020-01-30 |
| CA3068818A1 (en) | 2019-01-10 |
| US20230404992A1 (en) | 2023-12-21 |
| MA52924A (fr) | 2021-04-28 |
| US20250302818A1 (en) | 2025-10-02 |
| US20210145819A1 (en) | 2021-05-20 |
| JP2020527134A (ja) | 2020-09-03 |
| CN115300508A (zh) | 2022-11-08 |
| JP7288404B2 (ja) | 2023-06-07 |
| US11672792B2 (en) | 2023-06-13 |
| EP3648767A4 (en) | 2021-04-28 |
| WO2019007356A1 (en) | 2019-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020000029A (es) | Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon. | |
| EP4230627A3 (en) | Inhibitors of the menin-mll interaction | |
| AU2019410432B2 (en) | Quinoline derivatives for use in the treatment of inflammation diseases | |
| AU2018256591A1 (en) | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | |
| MX2016012262A (es) | Cenicriviroc para el tratamiento de fibrosis. | |
| PH12016501512A1 (en) | Treatment for resistant acne | |
| EA202090948A1 (ru) | Иммуномодуляция | |
| TN2015000434A1 (en) | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | |
| EP3270938A4 (en) | Methods and compositions relating to microbial treatment and diagnosis of skin disorders | |
| EA201690093A1 (ru) | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний | |
| EP4299122A3 (en) | Compositions and methods for treating skin and mucous membrane diseases | |
| EP3160493A4 (en) | Compositions and methods to regulate renalase in the treatment of diseases and disorders | |
| GT201600002A (es) | Bencil-1h-pirazolo[3,4-b]piridinas y su uso | |
| UY35693A (es) | Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso | |
| NZ751231A (en) | Silk-derived protein for treating inflammation | |
| EP3781576A4 (en) | BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| HK1257935A1 (zh) | 氨基糖苷衍生物及其在治疗遗传性病症中的应用 | |
| EP3185695A4 (en) | Preparation of soy protein products ("s810") | |
| EP3119387A4 (en) | Compositions for the treatment of dermatological diseases and disorders | |
| MX364528B (es) | Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas. | |
| MX2017010277A (es) | Cenicriviroc para el tratamiento de la fibrosis. | |
| MX2019004591A (es) | Metodo para preparar una formulacion inmunosupresora. | |
| AU2014216273A8 (en) | Topical ocular analgesic agents | |
| CL2015003780A1 (es) | Compuestos derivados pirimido-isoquinolin-quinonas, sus sales, isomeros, tautomeros farmacéuticas aceptables; composiciones farmáceuticas; procedimiento de preparación; y su uso en el tratamiento de enfermedades bacterianas y bacterianas multirresistentes. |